Wellington Management Group LLP decreased its holdings in shares of Evotec SE (NASDAQ:EVO - Free Report) by 12.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,299,905 shares of the company's stock after selling 334,529 shares during the quarter. Wellington Management Group LLP owned about 0.65% of Evotec worth $9,568,000 at the end of the most recent quarter.
Separately, DCF Advisers LLC boosted its position in shares of Evotec by 5.9% during the 4th quarter. DCF Advisers LLC now owns 229,871 shares of the company's stock worth $956,000 after purchasing an additional 12,816 shares during the period. 5.81% of the stock is owned by hedge funds and other institutional investors.
Evotec Stock Up 2.7 %
NASDAQ EVO traded up $0.09 on Tuesday, reaching $3.39. The stock had a trading volume of 35,826 shares, compared to its average volume of 139,149. The company has a quick ratio of 1.99, a current ratio of 2.09 and a debt-to-equity ratio of 0.43. The stock has a fifty day moving average price of $3.78 and a two-hundred day moving average price of $4.07. Evotec SE has a 12-month low of $2.84 and a 12-month high of $7.77.
Evotec Company Profile
(
Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
Recommended Stories
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
